Dupilumab has recently been recognized as a potential trigger for drug-induced sarcoid-like reactions (DISR). This phenomenon may become more prevalent with increased utilization of this drug for a multitude of skin and atopic conditions. We present a unique case of a patient developing a solitary cutaneous nodule on her left forearm following dupilumab initiation. Histopathology and MRI studies confirmed that this nodule had features of a sarcoid granuloma. Six months following dupilumab discontinuation, the patient's granuloma resolved. This case demonstrates that dupilumab can induce cutaneous-limited autoimmune disease and stresses the importance of prompt recognition of dupilumab-induced sarcoid-like reactions for appropriate diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Bash et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: